Steven L Roberds

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7504606/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurology, 2013, 49, 243-254.	1.0	1,185
2	Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurology, 2013, 49, 255-265.	1.0	693
3	BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Human Molecular Genetics, 2001, 10, 1317-1324.	1.4	644
4	Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy. Cell, 1994, 78, 625-633.	13.5	463
5	A role for dystrophin-associated glycoproteins and utrophin in agrin-induced AChR clustering. Cell, 1994, 77, 663-674.	13.5	361
6	Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatric Neurology, 2021, 123, 50-66.	1.0	230
7	Cloning and tissue-specific expression of five voltage-gated potassium channel cDNAs expressed in rat heart Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 1798-1802.	3.3	226
8	Rapsyn may function as a link between the acetylcholine receptor and the agrin-binding dystrophin-associated glycoprotein complex. Neuron, 1995, 15, 115-126.	3.8	202
9	Primary adhalinopathy: a common cause of autosomal recessive muscular dystrophy of variable severity. Nature Genetics, 1995, 10, 243-245.	9.4	192
10	ANALYSIS OF NOVEL DISEASE-RELATED GENES IN BRONCHIAL ASTHMA. Cytokine, 2002, 19, 287-296.	1.4	181
11	Non-muscle alpha-dystroglycan is involved in epithelial development Journal of Cell Biology, 1995, 130, 79-91.	2.3	179
12	Heteromultimeric assembly of human potassium channels. Molecular basis of a transient outward current?. Circulation Research, 1993, 72, 1326-1336.	2.0	171
13	Disease mechanisms revealed by transcription profiling in SOD1-G93A transgenic mouse spinal cord. Annals of Neurology, 2001, 50, 730-740.	2.8	128
14	Circulating Succinate is Elevated in Rodent Models of Hypertension and Metabolic Disease <subtitle />. American Journal of Hypertension, 2007, 20, 1209-15.</subtitle 	1.0	122
15	Highly degenerate, inosine-containing primers specifically amplify rare cDNA using the polymerase chain reaction. Nucleic Acids Research, 1988, 16, 10932-10932.	6.5	111
16	Clustering and immobilization of acetylcholine receptors by the 43-kD protein: a possible role for dystrophin-related protein Journal of Cell Biology, 1993, 123, 729-740.	2.3	107
17	A cluster of novel serotonin receptor 3-like genes on human chromosome 3. Gene, 2003, 319, 137-148.	1.0	88
18	A common missense mutation in the adhalin gene in three unrelated Brazilian families with a relatively mild form of autosomal recessive limb-girdle muscular dystrophy. Human Molecular Genetics, 1995, 4, 1163-1167.	1.4	75

STEVEN L ROBERDS

#	Article	IF	CITATIONS
19	Molecular Biology of the Voltage-Gated Potassium Channels of the Cardiovascular System. Journal of Cardiovascular Electrophysiology, 1993, 4, 68-80.	0.8	67
20	Functional characterization of RK5, a voltage-gated K+channel cloned from the rat cardiovascular system. FEBS Letters, 1991, 295, 211-213.	1.3	59
21	Discovery of Potent Inhibitors of Soluble Epoxide Hydrolase by Combinatorial Library Design and Structure-Based Virtual Screening. Journal of Medicinal Chemistry, 2011, 54, 1211-1222.	2.9	56
22	Genetic heterogeneity for Duchenne-like muscular dystrophy (DLMD) based on linkage and 50 DAG analysis. Human Molecular Genetics, 1993, 2, 1945-1947.	1.4	50
23	A 5′ Dystrophin Duplication Mutation Causes Membrane Deficiency of -Dystrog ycan in a Family with X-linked Cardiomyopathy. Journal of Molecular and Cellular Cardiology, 1997, 29, 3175-3188.	0.9	49
24	Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning Conference. Pediatric Neurology, 2016, 60, 1-12.	1.0	43
25	Developmental expression of cloned cardiac potassium channels. FEBS Letters, 1991, 284, 152-154.	1.3	41
26	Increased electroencephalography connectivity precedes epileptic spasm onset in infants with tuberous sclerosis complex. Epilepsia, 2019, 60, 1721-1732.	2.6	37
27	Chromosomal mapping in the mouse of eight K + -channel-genes representing the four Shaker -like subfamilies Shaker, Shab, Shaw , and Shal. Genomics, 1993, 18, 568-574.	1.3	34
28	Oral Delivery of 1,3â€Dicyclohexylurea Nanosuspension Enhances Exposure and Lowers Blood Pressure in Hypertensive Rats. Basic and Clinical Pharmacology and Toxicology, 2008, 102, 453-458.	1.2	34
29	Rapid, Computer Vision-Enabled Murine Screening System Identifies Neuropharmacological Potential of Two New Mechanisms. Frontiers in Neuroscience, 2011, 5, 103.	1.4	29
30	Abnormal expression of laminin suggests disturbance of sarcolemma-extracellular matrix interaction in Japanese patients with autosomal recessive muscular dystrophy deficient in adhalin Journal of Clinical Investigation, 1994, 94, 601-606.	3.9	27
31	High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex. Epilepsy Research, 2018, 148, 1-7.	0.8	25
32	Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex. Neuropharmacology, 2020, 180, 108297.	2.0	23
33	Pilot Study of Neurodevelopmental Impact of Early Epilepsy Surgery in Tuberous Sclerosis Complex. Pediatric Neurology, 2020, 109, 39-46.	1.0	23
34	The Expression of Dystrophin-associated Glycoproteins During Skeletal Muscle Degeneration and Regeneration. An Immunofluorescence Study. Journal of Neuropathology and Experimental Neurology, 1995, 54, 557-569.	0.9	22
35	Pharmacokinetic evaluation of a 1,3-dicyclohexylurea nanosuspension formulation to support early efficacy assessment. Nanoscale Research Letters, 2007, 2, 291-296.	3.1	21
36	Tuberous Sclerosis Complex Genotypes and Developmental Phenotype. Pediatric Neurology, 2019, 96, 58-63.	1.0	21

STEVEN L ROBERDS

#	Article	IF	CITATIONS
37	1,3-Dicyclohexyl urea nanosuspension for intravenous steady-state delivery in rats. Journal of Experimental Nanoscience, 2007, 2, 239-250.	1.3	18
38	α-Dystroglycan deficiency correlates with elevated serum creatine kinase and decreased muscle contraction tension in golden retriever muscular dystrophy. FEBS Letters, 1994, 350, 173-176.	1.3	13
39	Approach to Preventive Epilepsy Treatment in Tuberous Sclerosis Complex and Current Clinical Practice in 23 Countries. Pediatric Neurology, 2021, 115, 21-27.	1.0	13
40	CLINICAL AND MOLECULAR PATHOLOGICAL FEATURES OF SEVERE CHILDHOOD AUTOSOMAL RECESSIVE MUSCULAR DYSTROPHY IN SAUDI ARABIA. Developmental Medicine and Child Neurology, 1996, 38, 262-270.	1.1	12
41	Expression of Deletion-Containing Dystrophins in mdx Muscle: Implications for Gene Therapy and Dystrophin Function. Pediatric Research, 1995, 37, 693-700.	1.1	11
42	Inhibition of MEK-ERK signaling reduces seizures in two mouse models of tuberous sclerosis complex. Epilepsy Research, 2022, 181, 106890.	0.8	10
43	Impacting development in infants with tuberous sclerosis complex: Multidisciplinary research collaboration American Psychologist, 2019, 74, 356-367.	3.8	9
44	Adhalin gene polymorphism. Human Molecular Genetics, 1994, 3, 2269-2269.	1.4	8
45	Adhalin mRNA and cDNA sequence are normal in the cardiomyopathic hamster. FEBS Letters, 1995, 364, 245-249.	1.3	8
46	Patient Voice in Rare Disease Drug Development and Endpoints. Therapeutic Innovation and Regulatory Science, 2017, 51, 257-263.	0.8	7
47	The Impact of Psychiatric Symptoms on Tuberous Sclerosis Complex and Utilization of Mental Health Treatment. Pediatric Neurology, 2019, 91, 41-49.	1.0	7
48	Epilepsy Community at an Inflection Point: Translating Research Toward Curing the Epilepsies and Improving Patient Outcomes. Epilepsy Currents, 2021, 21, 385-388.	0.4	3
49	Exploring the Foundation of Genomics: A Northern Blot Reference set for the Comparative Analysis of Transcript Profiling Technologies. Comparative and Functional Genomics, 2004, 5, 584-595.	2.0	2
50	Effect of the antiviral compound MDL 20,610 on some aspects of murine immune function. International Journal of Immunopharmacology, 1988, 10, 639-649.	1.1	1
51	Commentary on Asato et al., "Epilepsy and comorbidities—What are we waiting for?― Epilepsy and Behavior, 2014, 34, 136.	0.9	1
52	Immunogold localization of adhalin, α-dystroglycan and laminin in normal and dystrophic skeletal muscle. Biochemical Society Transactions, 1996, 24, 274S-274S.	1.6	0
53	Applying genomics tools to identify therapeutic targets for asthma. Expert Opinion on Investigational Drugs, 1998, 7, 1301-1312.	1.9	0
54	Partnering to support the next generation of epilepsy researchers. Epilepsy and Behavior, 2017, 75, 258-260.	0.9	0